| Literature DB >> 27110824 |
Pamela Lazar-Karsten1, Gazanfer Belge2, Detlev Schult-Badusche3, Tim Focken4, Arlo Radtke5, Junfeng Yan6, Pramod Renhabat7, Salah A Mohamed8.
Abstract
Thoracic aortic dilation is the most common malformation of the proximal aorta and is responsible for 1%-2% of all deaths in industrialized countries. In approximately 50% of patients with a bicuspid aortic valve (BAV), dilation of any or all segments of the aorta occurs. BAV patients with aortic dilation show an increased incidence of cultured vascular smooth muscle cell (VSMC) loss. In this study, VSMC, isolated from the ascending aorta of BAV, was treated with Simian virus 40 to generate a BAV-originated VSMC cell line. To exclude any genomic DNA or cross-contamination, highly polymorphic short tandem repeats of the cells were profiled. The cells were then characterized using flow cytometry and karyotyping. The WG-59 cell line created is the first reported VSMC cell line isolated from a BAV patient. Using an RT² Profiler PCR Array, genes within the TGFβ/BMP family that are dependent on losartan treatment were identified. Endoglin was found to be among the regulated genes and was downregulated in WG-59 cells following treatment with different losartan concentrations, when compared to untreated WG-59 cells.Entities:
Keywords: WG-59 cell line; bicuspid aortic valve; losartan; vascular smooth muscle cell
Year: 2016 PMID: 27110824 PMCID: PMC4931668 DOI: 10.3390/cells5020019
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1(A) Initial foci of transformed cells 26 days post-transfection in the bright field microscope. Foci are clearly distinguishable among the cultured and transfected cells. (B) GFP-labeled T-antigen expression in transfected cells. (C) Immortalized confluent WG-59 in comparison with non-transfected, primary confluent VSMCs; 10-fold enlargement (D). (E) WG-59 cell culture, third day of 20. Passage; 10-fold enlargement. (F) WG-59 cell culture, sixth day of 20. Passage; 10-fold enlargement.
Karyotype of the examined immortalized cell culture showing several aberrations in different chromosomes. SKY, spectral karyotyping.
| Composite Karyotype SKY: |
|---|
| 70-91,XX,-Y[11],-Y[12],der(2)t(2;6)x2[11],-3[3],-4[4],der(6)t(6;15)[2],der(6)t(6;15der(8)t(9;8;2)x2[12],der(8)t(8;18)[7],der(8)t(8;18)x2[5],-9[4],+9[2],der(9)t(5;9)[5],der(9)t(5;9)x2[6],-10[4],-11[3],der(11)t(8;11)x2[7],der(12)t(5;12)x2[4],-13[7],-13[3],rob(13;14)[4],rob(13;14)x2[7],-14[5],-14[7],der(14)t(14,19)[4],der(14)t(14,19)x2[4],-15[12],-15[12], der(15)t(15;16)x2[9],-16[5], del(16)x2[8],der(16)t(16;20)x2[3],-17[4],-18[11],-18[7],der(18)t(5;18)[2],der(18)t(11;18)x2[7],-19[2]-19[10],-20[3],-20[2],der(20)t(20;22)x2[9],-21[3],-22[12],-22[12][cp12] |
Figure 2Illustration of detected chromosomes in WG-59 immortalized cultured cells in display colors, showing a pseudotriploid cell line with several aberrations.
Allelic list of the WG-59 cell line and tissue donor STR loci profiling using 8 different polymorph loci, performed by DSMZ, Germany, showing that these two samples are of the same origin.
| Marker | WG-59 Cells | WG-59 Tissue |
|---|---|---|
| D5 | 10 | 10 |
| D5’ | 12 | 12 |
| D13 | 11 | 11 |
| D13’ | 11 | 11 |
| D7 | 9 | 9 |
| D7’ | 10 | 10 |
| D16 | 12 | 12 |
| D16’ | 13 | 13 |
| vWA | 14 | 14 |
| vWA’ | 15 | 15 |
| TH01 | 9 | 9 |
| TH01’ | 9.3 | 9.3 |
| TPOX | 8 | 8 |
| TPOX’ | 11 | 11 |
| CFS1 | 11 | 11 |
| CSF1’ | 11 | 11 |
| Amel | X | X |
| Amel’ | X | Y |
Figure 3Electropherogram of the short tandem repeat (STR) profiling of (A) the WG-59 cell line and (B) the WG-59 donor tissue.
Figure 4Purity analysis of isolated VSMCs with flow cytometry showing α-actin and myosin heavy chain-positive cells at the 20th passage and 80%–90% confluency. (A) Isotype control; (B) WG-59 cells; (C–D) purity analysis of isolated VSMCs with flow cytometry showing α-actin- and calponin-positive cells at the 20th passage and 80%–90% confluency; (E–F) purity analysis of isolated VSMCs with flow cytometry showing myosin heavy chain- and calponin-positive cells at the 20th passage and 80%–90% confluency; (G–H) purity analysis of isolated VSMCs with flow cytometry showing smoothelin and the isotype control of WG-59 cells at the 20th passage and 80%–90% confluency. Histogram plot of Smoothelin expression (G). Isotype control in pseudo color plot (H).
Figure 5Correlation between the signal intensities of TGFβ-pathway genes. Expression analysis in losartan-treated and untreated cells. Cells treated with losartan are plotted against untreated cells. The scatter plot shows a positive tendency with a strong correlation between the two samples.
Significantly regulated genes in WG-59 after losartan-treatment compared to untreated cells. −, downregulation; +, upregulation.
| Gene | Description | Gene Bank | Fold Change | |
|---|---|---|---|---|
| 1 µM Losartan | ||||
| Activin A receptor, type IIA | NM_001616.3 | −1.16 | 0.0274 | |
| BMP and activin membrane-bound inhibitor | NM_012342.2 | −1.10 | 0.0273 | |
| Bone morphogenetic protein 4 | NM_001202.3 | −1.12 | 0.0325 | |
| BMP binding endothelial regulator | NM_133468 | −1.16 | 0.0121 | |
| Cell division cycle 25A | NM_001789.2 | −1.24 | 0.0008 | |
| Cystatin C | NC_000020.10 | −1.11 | 0.0305 | |
| Endoglin | NM_000118 | −1.14 | 0.0052 | |
| Follistatin | NM_013409 | −1.13 | 0.0099 | |
| Growth Differentiation Factor 5 | NM_000557 | −1.26 | 0.0091 | |
| Jun Proto-Oncogene | NM_002228 | −1.06 | 0.0479 | |
| Plasminogen Activator, urokinase | NM_002658 | −1.07 | 0.0052 | |
| SMAD family member 3 | NM_005902 | 1.01 | 0.0335 | |
| SRY (sex determining region Y)-box 4 | NM_003107 | −1.25 | 0.0061 | |
| Signal transducer and activator of transcription, 1.91 kD | NM_007315 | −1.08 | 0.0015 | |
| Transforming growth factor beta 1 | NM_000660 | 1.02 | 0.0460 | |
| Transforming growth factor, beta-induced, 68 kDa | NM_000358 | −1.12 | 0.0316 | |
| Transforming growth factor beta, receptor 1 | NM_004612 | −1.20 | 0.0028 | |
| Hypoxanthine phosphoribosyltransferase1 | NM_000194 | −1.04 | 0.0396 |
Figure 6Single real-time RT-PCR of endoglin after WG-59 treatment with increasing losartan concentrations. Increasing the losartan concentration could not downregulate endoglin expression significantly.